Discontinuing Coverage on Dalrada (DFCO).
We Are Temporarily Discontinuing Coverage on Dalrada Financial.
Great little company and we're up 400%. But with the market...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Newsletter: Institutional Analyst. And Yes, We Have Another Double.
1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....
Video: Mel Gibson Stem Cell Testimonial.
Fascinating Interview with Joe Rogen, Mel Gibson, and Dr. Neil Riordan, Early Pioneer and Stem Cell Expert.
Joe Rogan...
Old News, But Wow: Starr Foundation Reaffirms Support for Stem Cell Research with $50...
Someone is a Big Believer and Cutting Equally Big Checks!
NEW YORK (April 4, 2019) — The Starr...
Organicell (BPSR) a Triple Since Easter.
Slowly she turns, step-by-step. $20 million gain in market value. Spurred by FDA Emergency IND's.
RELATED: Adding Organicell (BPSR)...
The FDA Cracks Down On Stem Cell Therapy.
Due to a somewhat unexpected crackdown on stem cell treatment centers a couple of weeks ago - we have decided to hold...
Stem Cell Play Organicell (BPSR) Screams Higher.
Stock Levitates After Series of Positive Press Releases on Zofrin.
Added to the Watch List in April a...
Make Hay While the Sun Shines. Up 6,400%.
Celcius (CELH) We're Up 6,400%. Alkaline Water (WTER) We're Up 12%.Dicerna (DRNA) We're Up 700%. Ready to Breakout?BioSig (BSGM) We Have...
Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.
The 2021 Biotech Six Pack: Stocks We Expect to Double!
These are ideas #3 and #4 for the 'Biotech...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
